Anthracycline-induced cardiotoxicity. A case presentation
Abstract
A case attended in the “Dr. Antonio Luaces Iraola” Provincial Hospital of Ciego de Avila is presented,that it considers important for its little frequency. A 54-year-old woman with injury in the palate, of big
size, rounded, of hard and irregular surface, to which some studies are carried out and it diagnosed to
her a quite differentiated Non-Hodgkin Lymphoma. It offers chemotherapy treatment of 8 cycles every
21 days, to 7th cycle with an accumulate dose of doxorubicin 660mg/m2, begins with dyspnea to the
big efforts, its clinical condition was worsening and she arrives to the Hospital with an acute pulmonary
edema, clinical studies were carried out. The case is concluded with dilated cardiomyopathy
diagnosis.
Downloads
Author Biographies
Mayelin Baró Rojas
Edmundo Luis Sánchez González
Wilfredo García Sotolongo
References
Braunwald E. Braunwald Heart Disease. 7 ed. New York: Saunders; 2005.
Lipshutz S. Late cardiac efects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Eng J Med. 2003; 324:808-15.
Kesevan S. Anthracycline-induced cardiotoxicity. Ann Intern Med. 2006; 125:47-58.
Von Hoff D. Daunomycin-induced cardiotoxity in children and adults. Am J Med. 1997; 62:200-8.
Arsen Rl. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 2006; 70:73-77.
Steinherz L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Ass. 2008; 266:1672-7.
Geiger S, Lange V. Suhl P, Heinemam V, Stembler HJ. Anticancer therapy induced cardiotoxicity review of the literature. Anticancer Drugs. 2010: 21(6): 578-90.
Shan K, Lincoff AM. Young JB. Antrathracycline induced cardiotoxicity. Ann Inter Med. 1996; 125(1): 47-58.
Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol [Internet]. 1991 [citado 23 Ene 2013]. 9(7): 1215-1223. Disponible en: http://jco.ascopubs.org/content/9/7/1215.short
Nieto Y, Cagnoni A. Cardiac toxicity following high dose ciclophosphamide, cisptatin, and BNC (stamp-I) for breast cancer. Biol Blood Marrow Transpl. 2012; 6(2A): 198-2003.
Kerkela R, Gazette l. Cardiotoxicity of the cancer therapheutic agent imatinibmesylate. Nat Med. 2006; 12(8): 908-16.
Rosti G, Martinelli G. Cardiotoxiciti of the chemotherapeutic agents: incidence treatment and prevention. Drug Safety. 2011; 22:302.
Stemmber HJ. Anticancer therapy induced cardiotoxicity review of the literature. Anticancer Drugs. 2010; 21(6): 578-90.
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.
The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.
